Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

inhibitor of multiple protein tyrosine phosphatases (PTPases), specifically the src homology PTPase (SHP-1 & SHP-2) and PTP1B. Lenocta has also been demonstrated to augment cytokine signaling and responses in hemopoietic cell lines, which can enhance the body's immune system. Preclinical testing of Lenocta has demonstrated anti-tumor activity against a wide spectrum of cancers.

About PTPases

The protein tyrosine phosphatase superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signaling pathways that underlie a broad spectrum of fundamental physiological processes and represent a new class of therapeutic targets. The PTPases SHP-1 and SHP-2 modulate progenitor cell development, cellular growth, tissue inflammation, cellular chemotaxis, and directly control cell survival involving oxidative stress pathways. SHP-1 and SHP-2 are fundamental for the function of several growth factor and metabolic pathways with far reaching implications for disease pathways and disorders such as diabetes, neurodegeneration, and cancer.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious diseases. VioQuest has three targeted drug candidates in clinical development: VQD-002 which inhibits Akt, a member of the serine/threonine-specific protein kinase family that is amplified, overexpressed, and/or activated in prostate, breast, ovarian, colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1, SHP-2, and PTP1B that has demonstrated clinical and biological activity in solid tumors; and Xyfid(TM), a topical therapy which is being developed for the treatment and prevention of chemotherapy-induced Hand-Foot Syndrome (HFS). VioQuest anticipates commencing Phase II trials for VQD-002, and
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today announced ... other conditions, shares of its common stock in an underwritten public ... the offering may be completed, or as to the actual size ... is acting as sole book-running manager for the offering.  ...
... Gore & Associates is among just five workplaces to ... to Work For" since the rankings debuted three decades ... its workforce, earned the No. 38 spot on the ... (Photo:  http://photos.prnewswire.com/prnh/20120119/PH38553 ) Headquartered in Newark, Del., ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2W. L. Gore & Associates Named a Top U.S. Workplace 2
(Date:8/29/2015)... ... 2015 , ... Brands like Toppik , Eau Thermale Avene and Bliss ... a threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer ... shipping for customers regardless of the item’s selling price.” , With competitive pricing in ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... with stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed ... to improve treatment outcomes. This localized treatment seems to address the symptoms ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... , FRIDAY, Dec. 30 (HealthDay News) -- ... and skaters should take simple safety precautions, orthopedic experts ... that in 2010 more than 440,000 people were treated ... among snowboarders and skiers. These two sports accounted for ...
... Two recent studies by Van Andel Research Institute scientists ... distinct kidney cancer subtypes, which could pave the way for ... Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, ... of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive ...
... Dennis Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... was 19 years old. Then a sophomore studying physics at ... and depression for years. He said he,d self-medicated by drinking and ... demons that had been gnawing at his soul for years burst ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... -- A new review of existing research suggests that, despite ... heart patients should get Plavix, a blood-thinning drug used to ... clopidogrel, is used to treat or prevent blood clots due ... as balloon angioplasty. But some patients ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... are typically thought to be diseases of young women and ... drive a young person to an eating disorder may linger ... are coming forward to receive treatment for eating problems that ...
Cached Medicine News:Health News:Tips to Keep Winter Sports Injury-Free 2Health News:Tips to Keep Winter Sports Injury-Free 3Health News:Van Andel Research Institute findings provide more complete picture of kidney cancer 2Health News:Virginia Man Won't Let His Mental Illness Define Him 2Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Doubt Cast on Use of Genetic Test Before Plavix 2Health News:Eating Disorders Can Last Well Beyond Teen Years 2Health News:Eating Disorders Can Last Well Beyond Teen Years 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
Medicine Products: